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Summary Increased expression of alternatively spliced variants of the CD44 family ofcell adhesion molecules
has been associated with tumour metastasis. In the present study, expression of alternatively spliced variants of
CD44 and their cellular distribution have been investigated in human colonic tumours and in the corresponding
normal mucosa, in addition to benign adenomatous polyps. The expression of CD44 alternatively spliced
variants has been correlated with tumour progression according to Dukes' histological stage. CD44 variant
expression was determined by immunohistochemisty using monoclonal antibodies directed against specific
CD44 variant domains together with RT-PCR analysis of CD44 variant mRNA expression in the same tissue
specimens. We demonstrate that as well as being expressed in colonic tumour cells, the full range of CD44
variants, CD44v2-vlO, are widely expressed in normal colonic crypt epithelium, predominantly in the crypt
base. CD44v6, the epitope which is most commonly associated with tumour progression and metastasis, was
not only expressed by many benign colonic tumours, but was expressed as frequently in normal basal crypt
epithelium as in malignant colonic tumour cells, and surprisingly, was even absent from some metastatic
colorectal tumours. Expression ofnone ofthe CD44 vanant epitopes was found to be positively correlated with
tumour progression or with colorectal tumour metastasis to the liver, results which are inconsistent with a role
for CD44 variants as indicators of colonic cancer progression.
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CD44 is a widely distributed cell adhesion molecule that has
been implicated in the metastasis of epithelial tumours
(Giinthert et al., 1991; Heider et al., 1993) and lymphomas
(Jalkanen et al., 1991; Sy and Guo, 1991). There are multiple
CD44 isoforms generated by alternative splicing of up to 12
exons, leading to the expansion of a basic 'haematopoietic'
transcript (CD44s) into a large family of molecules with
potentially diverse functions (Screaton et al., 1992). CD44s is
a major cell-surface receptor for hyaluronate and mediates
cell-extracellular matrix (ECM) adhesion (Aruffo et al.,
1989), and also lymphocyte trafficking via the lymph node
high endothelium (Jalkanen et al., 1988).
A range of CD44 alternatively spliced variants, the
functions of which are unknown, are expressed in low
abundance on some cells of epithelial origin (Terpe et al.,
1994), and are also transiently expressed by activated
lymphocytes together with CD44s (Koopman et al., 1993).
A link between CD44 expression, tumour progression and
metastasis has been suggested by studies demonstrating an
up-regulation of CD44s and CD44 variants in certain
tumours (Jalkanen et al., 1991; Stamenkovic et al., 1989;
Wielenga et al., 1993; Hart et al., 1991). The most compelling
evidence, however, has come from studies employing animal
models, in which transfection of rat CD44 cDNAs containing
v6 (exon 10) and v7 (exon 11) into non-metastasising cell
lines results in creation of a mestastatic phenotype (Giinthert
et al., 1991; Rudy et al., 1993). Metastasis in these models
can be inhibited by co-treatment with monoclonal antibodies
directed against CD44s (Guo et al., 1994), or CD44 variant
domains (Seiter et al., 1993). Isoforms of CD44 have been
identified in human tumours by either reverse transcription
polymerase chain reaction (RT-PCR) or immunohistochem-
istry (Heider et al., 1993; Jackson et al., 1992; Hofmann et
al., 1991), and the results suggest that a disruption in the
control of the splicing mechanism may occur in transformed
cells. The appearance of splice variants of CD44 occurs soon
after neoplastic transformation (Kim et al., 1994), and the
expression of the CD44v6 epitope, encoded by exon 10, has
been reported to correlate with tumour progression to more
advanced stages in colorectal cancer (Wielenga et al., 1993;
Mulder et al., 1995).
The observed expression of restricted epitope domains of
CD44 in metastatic tumours is important because it provides
the potential for both highly specific screening of tissue
biopsies for metastatic potential (Matsumura et al., 1992) and
for therapeutic targeting of mestastatic disease. However,
recent reports documenting expression of CD44v6 domain in
a few normal colonic tissues (Terpe et al., 1994; Fox et al.,
1994) and in bladder cancer (Southgate et al., 1995) question
the notion that expression of CD44 variants is indicative of
mestastatic disease and may imply a more complex biological
role for CD44 variants in normal cells as well as in neoplastic
cells.
In order to clarify the impact ofexpression of alternatively
spliced CD44 variants on colonic cancer progression, we have
undertaken a comprehensive study of CD44 variant
expression in a large sample of patients and compared the
malignant tumour specimens with corresponding normal
colonic mucosa from the same patients. We have included
benign adenomatous polyps as as well as tissues representa-
tive of the range of colorectal tumour progression through to
metastasis. As the best marker for colorectal tumour
progression remains the histological stage, we have corre-
lated CD44 variant epitope expression with Dukes'
histological stage of the tumour. Reverse transcriptase-
polymerase chain reaction (RT-PCR) and exon-specific
priming have been employed to identify specific mRNA
transcripts expressed and the cellular localisation of the
respective CD44 variant domains was studied by immuno-
histochemistry. Analysis of the expression of each of the
CD44 alternatively spliced exons, the epitopes encoded by
them and their cellular distribution should provide insight
into the significance of CD44 variant expression in colorectal
cancer.
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Materials and methods
Patients and tumour specimens
A total of 109 patients with colonic neoplasms (adenomatous
polyps, carcinomas or liver metastases) underwent colon-
scopic or surgical resection. Samples of tumour and normal
mucosa (at least 20 cm from the tumour) were obtained from
surgical specimens and portions were either processed for
routine histological examination or snap frozen in liquid
nitrogen for RNA analysis. Specimens of junctional
epithelium (between tumour and normal mucosa) were also
collected for immunohistochemical analyses (see below).
Tumours were staged pathologically according to a modified
Dukes' system where stage A is tumour confined to the bowel
wall, stage B is invasion through the wall, stage C is lymph
node involvement and stage D is the presence of distant
metastases.
Northern blot analyses
Total RNA was obtained from frozen tissue specimens by the
acid/guanidinium thiocyanate method of Chomczynski and
Sacchi (1987). RNA samples (10 ,ug) were electrophoresed on
1.2% denaturing agarose gels containing 1.1% formaldehyde
and blotted by capillary diffusion onto Hybond N nylon
membranes (Amersham, Castle Hill, Australia). The mem-
branes were hybridised essentially as described (Antalis and
Dickinson, 1992) and washed to a final stringency of
0.1 x SSC, 0.1% sodium dodecyl sulphate (SDS) at 650C.
Probes directed against specific CD44 variant exons were
generated by RT-PCR using total RNA isolated from either
the breast cancer cell line ZR75 or a colorectal hepatic
metastasis as templates. The amplified DNA was cloned into
pGEM-T (Promega, Madison, WI, USA) or pBluescript
(Stratagene, La Jolla, CA, USA) and characterised by DNA
sequence analysis. Seven CD44 variant probes were obtained
and designated pEx6, pEx7, pEx8, pEx9, pExlO, pExl1,
pEx12 - 14 (Figure la). The CD44 variant plasmid constructs
were radiolabelled by the random priming method for
Nothern blot analyses (Feinberg et al., 1983). Specific
CD44 sense and antisense riboprobes were transcribed in
vitro in the presence of [32P]UTP using SP6, T7 or T3
promoters as appropriate. Blots were reprobed with a
radiolabelled oligonucleotide against human 18S rRNA as a
measure of total RNA loaded in each lane (Antalis and
Dickinson, 1992). The blots were exposed to Kodak XK-1
film between Dupont Cronex intensifying screens at -700C
for varying times and quantitated by scanning different
exposures of autoradiographs using a scanning densitometer
(Molecular Dynamics) driven by ImageQuant software.
CD44 variant-specific reverse transcription polymerase chain
reaction (RT-PCR)
cDNA was synthesised from 5 ,ug of total RNA using AMV
reverse transcriptase (Promega) in the presence of oligo
dT(16- 18) (Pharmacia Biotech, Uppsala, Sweden) in a 25 ,l
reaction volume at 42°C for 60 min. In each experiment, 1 pl
of this reaction mixture was included in a 50 ,l PCR reaction
in the presence of 10 mM Tris HCI pH 8.3, 50 mM potassium
chloride, 2 mM magnesium chloride and 0.2 mM dNTP. The
PCR amplification conditions were: denaturation at 94°C for
2 min, annealing at 45°C for 1 min and extension at 72°C for
2 min for four cycles; then denaturation at 94°C for 30 s,
annealing at 55°C for 30 s and extension at 72°C for 2 min
for 28 cycles, with a final extension time of 7 min.
Detection and cloning of CD44 variant inserts
To determine the DNA sequences of the CD44 variants
expressed in the tissue specimens, variant inserts were isolated
by PCR amplification using primers which flank the proximal
membrane variant region: the forward primer derived from
the 5' sequence of exon 3, 3F (5'-TCCCAGTATGACACA-
TATTGC-3') and a reverse primer derived from exon 17, 17R
(5'-CCAAGATGATCAGCCATTCTGG-3') (Hoffman et al.,
1991) (Figure la). PCR products were separated by agarose
gel electrophoresis, purified and ligated into pGEM-T
(Promega). Transformants containing CD44 variant inserts
were identified and characterised by DNA sequence analysis.
Detection of variant domains by exon-specific priming
Atechniqueof'exon-specific' primingwasvalidatedandusedto
determine CD44 variant expression patterns in the tissue
specimens. In separate reactions, forward primers derived from
the5'sequencesofexon3(3F,describedabove), 6F(v2),7F(v3),
8F (v4), 9F (v5), lOF (v6), 1IF (v7) and 12F(v8) wereeach used
with a common reverse primer derived from exon 17 (17R, as
above). Thepositions oftheCD44variantprimers are shown in
Figure la and the sequences were as follows:
v2: 5'-GATGAGCACTAGTGCTACAGCAAC-3'
v3: 5'-GTACGTCTTCAAATACCATCTCAG-3'
v4: 5'-CAACCACACCACGGGCTTTTGACC-3'
v5: 5'-ATGTAGACAGAAATGGCACCACTG-3'
v6: 5'-TCCAGGCAACTCCTAGTAGTACAA-3'
v7: 5'-CAGCCTCAGCTCATACCAGCCATC-3'
v8: 5'-ATATGGACTCCAGTCATAGTACAA-3'
RNA isolated from each tissue specimen was reverse
transcribed with AMV reverse transcriptase. The cDNA was
used as the template for eight PCR reactions (1,l in each
reaction), each containing the common reverse primer 17R
and one of the forward primers above. The same cDNA was
used for the control reactions using primers 3F and 17R
which spans the entire variant region and controls for the
integrity of the mRNA and the reproducibility of the RT-
PCR process itself. Each PCR reaction mixture (10 MI per
lane) was resolved on a non-denaturing 1.2% agarose gel and
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Figure 1 (a) Schematic representation of the genomic structure
of the CD44 gene. Constitutively expressed exons, =; exons
capable of alternative splicing, M. Domains to which CD44
variant DNA probes, CD44 monoclonal antibodies and
oligonucleotide primers used in RT-PCR analyses are directed
are shown. (b) CD44 variant exons amplified by RT-PCR with
oligonucleotide primers 3F and 17R using RNA from four pooled
colonic tumours. Amplified products were cloned and charac-
terised by Southern blotting and DNA sequence analyses. The
CD44 variant exons detected, S~.CD44 variants and colorectal cancer progression
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Southern blotted by capillary transfer to a Hybond N nylon
membrane followed by hybridisation with radiolabelled
probes as described above.
a
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Immunohistochemistry
Monoclonal antibody (MAb) FIO-44-2 recognises a 'core'
domain of CD44s and was obtained from Serotec (Oxford,
UK). Other MAbs, 2C5 (subclass IgG2a, anti-CD44s), 3G5
(subclass IgG2b, anti-v3), 3D2 (subclass IgG,, anti-v4/5) 2F10
(subclass IgG1, anti-v6), 2G9 (subclass IgM, anti-v6) and 1E8
(subclass IgM, anti-v8/9) were produced as described (Fox et
al., 1994). Essentially mice were immunised with purified
soluble recombinant proteins generated by transfection into
COS1 cells of molecular chimaeras comprising CD44 variant
exon sequences fused to a CD33 signal sequence and an
IgG,-Fc sequence in pCDM8 (Invitrogen, The Netherlands).
The specificities of the MAbs obtained were determined by
immunostaining of specific CD44 variant constructs trans-
fected into COSI cells.
For immunohistochemical analyses of tissues, specimens
were embedded in OCT compound (Miles Laboratories,
Elkhart, IN, USA), quenched in liquid nitrogen and stored at
-70°C until sectioned. Frozen sections (5 jgm) were affixed to
Vectabond-treated slides (Vector Laboratories, Burlingame,
CA, USA) and air dried before fixation in equal parts
chloroform/acetone. After rehydration in phosphate-buffered
saline (PBS), endogenous peroxidase activity was inhibited
with 0.3% hydrogen peroxide and 0.1% sodium azide, and
non-specific antibody binding was inhibited by immersion in
4% non-fat skimmed milk powder. Endogenous biotin
activity was blocked with 0.1% avidin (Dakopatts, Carpin-
teria, CA, USA) followed by 0.01% D-biotin. Non-specific
antibody binding was further inhibited by preincubating
sections with 10% non-immune goat serum. Sections were
incubated with primary antibody (or no antibody for control)
for 30 min (RT), then biotinylated goat anti-mouse
immunoglobulins (Zymed, San Francisco, CA, USA)
followed by streptavidin -horseradish peroxidase complex
(Zymed). Antigenic sites were demonstrated using 3,3'-
diaminobenzidine as chromogen with hydrogen peroxide as
substrate. Sections were counterstained with Harris' haema-
toxylin and mounted in Permount.
CD44 expression was assessed with regard to staining
intensity (0, 1+, 2+ or 3+), proportion of positive cells
(<10%, 10-25%, 25-50%, 50-75% or >75%) and
localisation (basal cells, full thickness or scattered cells).
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Figure 2 Northern blot analysis of (a) normal colon (N) and
primary colonic tumours (P), and (b) normal liver (N) and
colorectal liver metastases (LM) using an antisense radiolabelled
riboprobe directed against the CD44v8-10 domain (CD44-E). As
a control for the amount of RNA loaded in each lane, each blot
was reprobed using a radiolabelled oligonucleotide directed
against 18S ribsomal RNA.
Statistical analyses
Comparative data were analysed using the Wilcoxon rank
sum test.
Results
Northern blot analysis detects CD44v8-10 expression but not
CD44v3- 7
A total of 37 colon tumours (polyps, n =6; Dukes' stages A,
n =8; B, n = 10 and C, n = 13) together with matched normal
colonic mucosa and 17 liver metastases were examined by
Northern blot analysis for expression of CD44 variants using
radiolabelled probes directed against exons v3, v6, v7 and
v8-10. Three CD44 mRNA transcripts containing v8- 10
(2.0 kb, 2.6 kb and 5.6 kb) were detected in all colonic
neoplasms including adenomatous polyps and liver metas-
tases. Representative blots are shown in Figure 2a and b.
These transcripts were not detected, however, in any
specimen of normal colonic mucosa (Figure 2a) nor in
normal liver tissues (Figure 2b) by Northern blot analysis.
Northern blots of the same tissue specimens hybridised with
variant-specific probes for v3, v6, and v7 resulted in detection
of no CD44 transcripts containing these variant exons, even
when the membranes were probed using sensitive in vitro
generated riboprobes. This may be due to the insensitivity of
the Northern blot technique in detecting low abundance
mRNA transcripts, which may also be compounded by the
use of shorter exon-specific probes in comparison with the
larger CD44v8 - 10 probe.
Multiple CD44 variant transcripts are detected by reverse
transcription-polymerase chain reaction (RT-PCR)
In order to detect the presence of low abundance alternatively
spliced CD44 mRNA transcripts, RT-PCR was employed
using primers flanking the proximal membrane extracellular
domain, 3F and 17R (see Figure la). Multiple amplified
products representing different CD44 variant transcripts were
detected in all specimens of normal colonic mucosa and
tumours analysed from 57 patients. A representative sample
is shown in Figure 3a. Both normal and neoplastic colon
tissues expressed both the standard (CD44s) (data not shown)
and epithelial (CD44E, CD44v8 10) transcripts. In addition,
these tisuses expressed slower migrating isoforms of CD44 as
shown in Figure 3a.
In order to examine the range of CD44 variant exons
expressed in the slower migrating isoforms, a technique
termed 'exon-specific' RT-PCR was used. cDNA was
amplified by PCR using exon-specific forward primers
together with a common reverse primer. 17R, SouthernCD44 variants and colorectal cancer progression
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Figure lb. The majority of the CD44 variant transcripts
identified by this technique (six out of eight) displayed a
sequential pattern of variant exon expression; i.e. if the first
variant exon used was v5, then v6, v7, v8, v9 and vlO were
also incorporated into the transcript. In two variants,
however, a discontinuous variant exon expression pattern
was obtained [v3, v5-vlO (no. 7) and v2-3, v8-10 (no. 8)]
and one of the transcripts was found to incorporate the full
range of variant exons, v2- 10 (no. 6).
Normal and neoplastic colon tissues express a wide range of
CD44 variant exons
roducts To evaluate CD44 variant exon expression in colonic
CD44 tumours and to attempt to correlate specific variant exons
playing with tumour progression, 'exon-specific' RT-PCR was
Lown in applied to a panel of colonic tumour tissues representative
of each stage of tumour progression according to Dukes'
stage, as well as benign adenomatous polyps. The presence of
each variant was scored and the percentage of tumours
expressing each CD44 variant exon was compared according
to Dukes' stage as shown in Figure 4. The data show that no
individual CD44 variant exon was clearly associated with
colorectal tumour progression and each variant exon from v2
-CD44E through to v8-vlO was detected in tumours from each
Dukes' stage. Expression of CD44vl was not detected in any
tissue specimen. Although vl is expressed in the mouse, it has
not been found in human CD44 alternatively spliced
transcripts (Screaton et al., 1993). CD44v2-containing
transcripts were detected in several tumour specimens; the
expression ofthis domain has not been reported previously in
human epithelial tumours. Several combinations of CD44
exon variants were detected in adenomatous polyps and
Dukes' A, B and C tumours, but transcripts containing all of
the CD44 variant exons (v2-vlO) were found only in
colorectal metastases in the liver (Dukes' D).
As observed for the colonic tumour specimens, normal
colonic mucosa also demonstrated similar heterogenity in the
patterns of CD44 variant exon usage and there was no
consistent pattern in the variant exon usage with progression
to malignancy (data not shown). Examples of 'exon-specific'
RT-PCR performed on normal mucosa from two patients
compared with their malignant counterparts are shown in
Figure 5. In Figure 5a, the normal colonic mucosa expresses
CD44 variant exons v4, v5, v7 and v8-vlO in common with
the corresponding colonic adenocarcinoma, and the colonic
Lane 1 2 S 4 5 b /
Figure 3 Southern blot analysis of CD44 variants amplified by
RT-PCR. (a) cDNA obtained from RNA isolated from normal
colon (N), primary colonic tumours (P), normal liver (NL) and
colorectal liver metastases (ML) was amplified using primers
flanking the proximal membrane extracellular domains, 3F and
17R. Amplification products were separated on 1.2% agarose
gels, transferred to nylon membrane and probed with radiola-
belled pExl2- 14, a plasmid containing the CD44 variant region
of CD44E. (b) The 'exon-specific' priming technique to detect
specific CD44 variant exon usage in colorectal tissues. cDNA
derived from a colorectal liver metastasis containing the full range
of CD44 variant exons was amplified using forward primers 6F,
7F, 8F, 9F, lOF, 1 F, 12- 14F respectively and the reverse primer
17R. The amplification products were analysed on replicate 1.2%
agarose gels and each gel blotted onto a Hybond N nylon
membrane. The seven identical blots obtained were each
hybridised with a different radiolabelled plasmid containing the
CD44 variant exons v2 (pEx6), v3 (pEx7), v4 (pEx8), v5 (pEx9),
v7 (pExl1), or v8-10 (pEx 12-14) to show the specific variant
domains and the utility of the technique. Thus, analysis of a
template of unknown CD44 variant composition, using the
conditions in the bottom blot (pExl2-14 to probe the panel of
PCR reactions each primed with a different forward primer) will
give a comprehensive profile of the specific CD44 variant exons
present in that specimen, i.e. a positive signal in lane 1 indicating
the presence ofexon 6 (v2), lane 2 the presence ofexon 7 (v3), etc.
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Figure 4 The pattern of CD44 variant exon usage in colorectal
tumours grouped according to Dukes' histological staging. Exon-
specific RT-PCR was performed on RNA isolated from colonic
tumour specimens from 57 patients as described in Materials and
methods. Amplification products were analysed by Southern
blotting and probed with radiolabelled plasmids containing exon-
specific cDNA sequences. The percentage of tumours expressing
each CD44 variant exon was determined according to Dukes'
stage as indicated. The number of specimens in each group are:
polyps (_), n =6; Dukes' A ([I), n =8; Dukes' B (0 ),
n=10; Dukes' C ( ), n=13; Dukes' D (1MM1), n=17.CD44 variants and colorectal cancer progression
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adenocarcinoma expresses an additional v3 exon not detected
in the normal mucosa. While the specific exon pattern
observed in this patient is not necessarily typical (see Figure
5b), it was commonly observed that CD44 variants expressed
in normal mucosa were maintained in corresponding
tumours, often with a concomitant increase in one or several
additional exons in the tumours only. In some patients,
however, a clear progressive increase in exon usage followed
progression from normal mucosa to primary adenocarcinoma
and subsequently to metastasis in the tissue specimens. For
example, in Figure 5b, the primary adenocarcinoma from
patient no. 182 shows the appearance of v5 and v7 in
addition to v3, v4 and v8-10 detected in the normal mucosa
and the additional appearance of v6 in the liver metastasis. It
a
Patient no 66
C
is clear that, at the mRNA level, a complex and diverse array
of CD44 transcripts exists in some tissues, and that this
complexity is not only apparent in malignant tissue, but also
is present in benign colonic tumours and in normal mucosal
tissues.
CD44 variant domain expression in normal and neoplastic
colorectal tissues
While the results of RT-PCR analyses demonstrate a variety
of CD44 variant exons and transcripts in colorectal tissues,
this technique does not discriminate expression among
different cell populations within the tissues nor provide
information as to whether the exons expressed are translated
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Figure 5 CD44 exon usage determined by 'exon-specific' priming RT-PCR of colonic tumours and normal colonic mucosa from
two patients. Tissues were subjected to combined exon-specific RT-PCR and Southern blot analysis as described in Figure 3b, and
blots were hybridised with radiolabelled plasmid containing v8- 10 (pEx12- 14) as in the bottom blot in Figure 3b. NC, normal
colon; PC, primary colonic carcinoma; LM, colonic liver metastasis. Each of the lanes represents the CD44 variant domains
obtained using the common primer 17R and the forward primer indicated. The control sample (C) is the same template cDNA
amplified using 17R and 3F primers which covers the entire variant region. (a) Patient no. 66, (b) Patient no. 182.
CD44 variant exon
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iiiinto their respective protein domains. In order to address
these questions, we performed immunohistochemical analyses
on the same panel of tumours using junctional tissue
specimens and monoclonal antibodies directed against the
CD44 variants and colorectal cancer progression
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epitopes encoded by core CD44 as well as the CD44 variants.
Representative results of core CD44 and CD44 variant
staining are shown in Figure 6a-j and the frequency and
intensity of CD44 variant expression as determined by
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Figure 6 Photomicrographs of tissue sections stained with CD44 MAbs directed against variant epitopes. Normal colonic mucosal
epithelium stained with MAb F1O-44-2 which is directed against a core domain of CD44 (a). Primary colonic carcinoma (b) and
colonic carcinoma liver metastasis (c) stained with MAb 2C5 which is also directed against a core domain of CD44. Normal colonic
crypt base epithelium (d) and primary colonic carcinoma (e) stained with MAb 2F10 which is directed against CD44v6. Primary
colonic carcinoma stained with anti-CD44v6 MAb 2F10 showing absent CD44v6 expression (f) and heterogeneous CD44v6
expression (g). A benign adenomatous polyp (h) and a colonic carcinoma liver metastasis (i) stained with MAb 2F10 showing
CD44v6 expression. Primary colonic carcinoma (j) stained with MAb 3D2 directed against CD44v4/5. The apparent positive
staining of tissue macrophages in the specimens is a result of endogenous peroxidase activity.CDU variants and colorectal cancer progression
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staining the entire panel of tissue specimens are summarised
in Tables I and II respectively.
Core CD44 The core domains of CD44, detected by MAb
F10-44-2 and potentially representing all CD44 species (but
predominantly CD44s), were abundantly expressed on
muscle, stromal and infiltrating cells of normal colonic
mucosa and were predominant on normal colonic epithelial
cells in the basal crypts as shown in Figure 6a. A second
MAb, 2C5, which recognises the same CD44 core domains,
gave an identical staining pattern (data not shown). Core
CD44 domains were detected on normal colonic epithelial
cells in 61 of 62 specimens (Table IA). In other specimens
(n = 109) (Table 1B), core CD44 domains were detected in all
adenomatous polyps, in all but two primary adenocarcino-
mas and in all colorectal liver metastases. In the tumour
tissues, core CD44 was expressed by both tumour and
stromal cells and the distribution of core CD44 in the
tumours cells was heterogeneous as illustrated in Figure 6b.
In the liver, core CD44 domains were expressed by Kupffer
cells, macrophages, hepatic stromal cells as well as the
metastatic tumour cells, but no core CD44 was detected in
normal hepatocytes as shown in Figure 6c.
CD44v8/9 In contrast to core CD44, CD44v8/9 (detected
with MAb 1E8) was found in normal colonic epithelia in only
5 of 62 patients (Table IB), and was similarly localised to the
basal crypt epithelium (data not shown). Twenty-six out of a
total of 109 polyp and tumour specimens (24%) were positive
for CD44v8/9, which was detected in only low to moderate
intensity. Like core CD44 expression in tumour specimens,
distribution of CD44v8/9 was often heterogeneous in the
tumour cells (data not shown). The low frequency of positive
staining is surprising, as CD44v8/9 has been found in a
greater proportion of colonic tumours in other studies (Terpe
et al., 1994; Wielenga et al., 1993). This result may reflect a
lower binding affinity for the 1E8 monoclonal antibody
compared with the antibodies used by others (see Discus-
sion).
CD44v6 CD44v6 (detected with MAb 2F10) was present in
50 of 62 normal colonic mucosa specimens (81%) (Table IA)
and was detected on the colonic epithelium predominantly in
the crypt base as shown in Figure 6d. Stromal cells did not
demonstrate detectable CD44v6 staining. The apparent
staining of tissue macrophages is caused by endogenous
peroxidase activity. A similar proportion of polyps and
colorectal tumour specimens (85%) also stained positively for
CD44v6 (Table IB). As shown in Figure 6e, CD44v6
expression in tumour specimens was usually confined to the
colonic tumour cells. As observed for the other CD44 variant
exons, the expression of CD44v6 was heterogeneous; this
heterogeneity was most pronounced at the periphery of
tumour cell clumps as illustrated in Figure 6g. Some patterns
of CD44v6 expression were observed, however, which would
not be predicted for an epitope associated with tumour
progression. In six cases in which CD44v6 expression was
present in the normal basal crypt epithelium, it was not
detected in the adjacent malignant primary colonic tumour.
An example of this staining pattern is shown in Figure 6f. In
addition, abundant CD44v6 expression could be found in
benign adenomatous polyps as well as malignant colorectal
tumours that had metastasised to the liver, as shown in
Figure 6h and i respectively.
CD44v4/5 CD44v4/5 expression patterns were more re-
stricted in normal colonic mucosa than the CD44v6
domain, showing positive staining in only 12 of 62 (19%)
tissues (Table IA). Like CD44v6, CD44v4/5 was confined
mostly to the crypt base in normal mucosa (data not shown).
CD44v4/5 was detected in 42 of 109 polyps and colonic
tumour specimens (39%) as shown in Table IB. The
distribution of CD44v4/5 in these specimens was confined
to the colonic tumour cells as shown in Figure 6j.
CD44v3 The pattern of CD44v3 expression was similar to
that of CD44v4/5. Normal colonic mucosa stained positively
for CD44v3 in 18 of 62 (29%) cases. As seen with CD44v4/5,
the staining was mostly confined to the crypt base (data not
shown). CD44v3 was detected in 50 of 109 (46%) polyp and
colonic tumour specimens as shown in Table IB where
staining was again generally confined to the colonic tumour
cells (data not shown).
CD444v3, v4/5, and v6 epitopes were generally found
Table I Summary of immunohistochemical analysis of colonic tumour specimens
A Expression of CD44 exons in normal colonic mucosa corresponding to tumour specimens and stratified according to Duke's staging
of tumour progression
No. of specimens positive/total number of cases
Total Liver
CD44 specimens Polyp Dukes' A Dukes' B Dukes' C metastases
variant mAb (n = 62) (n = 13)' (n = 11) (n = 26)a (n = 24) (n = 35)b
Core CD44 2C5 and 61/62 (98%) 6/6 (100%) 11/11 (100%) 21/21 (100%) 23/24 (96%)
(CD44s) F1O-44-2
CD44v8/9 1E8 5/62 (8%) 1/6 (17%) 1/11 (9%) 0/21 (0%) 3/24 (13%)
(CD44E)
CD44v6 2F10 50/62 (81%) 5/6 (83%) 10/11 (91%) 17/21 (81%) 18/24 (75%)
CD44v4/5 3D2 12/62 (19%) 1/6 (17%) 4/11 (36%) 2/21 (9%) 5/24 (21%)
CD44v3 3G5 18/62 (29%) 3/6 (50%) 4/11 (36%) 8/21 (38%) 3/24 (13%)
aLack of assessable normal adjacent mucosa in some cases. bNormal colonic mucosa not available.
B Expression of CD44 exons in colonic tumours and stratified according to Dukes' staging of tumour progression
No. ofspecimens positive/total number of cases
Total Liver
CD44 specimens Polyp Dukes' A Dukes' B Dukes' C metastases
variant mAb (n=109) (n = 13) (n = 11) (n = 26) (n = 24) (n = 35)
Core CD44 2C5 and 107/109 (98%) 13/13 (100%) 11/11 (100%) 25/26 (96%) 23/24 (96%) 35/35 (100%)
(CD44s) F1O-44-2
CD44v8/9 1E8 26/109 (24%) 2/13 (15%) 4/11 (36%) 5/26 (19%) 6/24 (25%) 9/35 (26%)
(CD44E)
CD44v6 2F10 93/109 (85%) 11/13 (85%) 11/11 (100%) 23/26 (88%) 20/24 (83%) 28/35 (80%)
CD44v4/5 3D2 42/109 (39%) 2/13 (15%) 4/11 (36%) 13/26 (50%) 13/24 (54%) 10/35 (28%)
CD44v3 3G5 50/109 (46%) 7/13 (54%) 5/11 (45%) 12/26 (46%) 11/24 (46%) 15/25 (43%)CD44 variants and colorectal cancer progression
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Table II Semi-quantitative evaluation of immunohistochemical analysis of colonic tumour specimens
A Proportion of tumour cells positive for each CD44 variant epitope in positively staining tissues, stratified according to
Dukes' staging of tumour progression
Score representing the proportion of cells positivea [median (range)]
CD44 Polyp Dukes' A Dukes' B Dukes' C Liver
variant mAb nb n n n metastases n
Core CD44 2C5 and 5 (5) 13 5 (3,5) 11 5 (0,5) 25 5 (0,5) 23 5 (1,5) 35
(CD44s) F10-44-2
CD44v8/9 1E8 2-3 (1,5) 2 1 (1,2) 4 2 (2,4) 5 2-3 (1,5) 6 2 (1,5) 9
(CD44E)
CD44v6 2F10 4 (1,5) 11 4 (1,5) 11 4 (1,5) 23 4 (2,5) 20 4 (2,5) 28
CD44v4/5 3D2 3 (3) 2 3-4 (3,4) 4 2 (1,5) 13 3 (1,5) 13 2-3 (1,5) 10
CD44v3 3G5 2-3 (1,5) 7 3 (3) 5 2 (1,5) 12 3-4 (2,5) 11 3 (2,5) 15
aValues signify: 1, < 10%; 2, 10-25%; 3, 25-50%; 4, 50-75%; 5, >75% of tumour cells. bNumber ofcells in each group staining positive.
B Intensity of staining in positive cells and stratified according to Dukes' staging of tumour progression
Intensitya [median (range)]
CD44 Polyp Dukes' A Dukes' B Dukes' C Liver Normal
variant mAb nb n n n metastases n crypt cells n
Core CD44 2C5 and 2 (2) 13 2 (2) 11 2 (0,3) 25 2 (1,3) 23 2 (1,3) 35 2 (0,3) 61
(CD44s) F10-44-2
CD44v8/9 1E8 1 (1,2) 2 1 (1,2) 4 2 (1,2) 5 1-2 (1,2) 6 1 (1,2) 9 1 (1,2) 5
(CD44E)
CD44v6 2F10 2 (1,3) 11 2 (1,3) 11 2 (1,3) 23 2 (1,3) 20 2 (1,2) 28 2 (1,3) 50
CD44v4/5 3D2 2 (2) 2 2 (1,2) 4 2 (1,2) 13 2 (1,2) 13 2 (1,2) 10 2 (1,2) 12
CD44v3 3G5 1-2 (1,2) 7 2 (1,3) 5 1-2 (1,2) 12 1-2 (1,2) 11 2 (1,3) 15 2 (1,3) 18
aValues signify: 1, +; 2, + +; 3, + + + intensity ofstaining. bNumber ofcells in each group staining positive.
throughout the basal crypt epithelium of normal colonic
mucosa. It should be noted, however, that some exceptions to
this pattern were observed. For example, in 11 patients,
CD44v3, v4/5 and v6 epitopes were expressed by those
normal colonocytes adjacent to the growing tumour margin
and not in the more distant normal epithelial cells (data not
shown). The significance of this expression pattern in these
specimens is not known.
CD44v6 is the variant exon that has been most frequently
associated with metastasis (see Wielenga et al., 1993). The
results given in Tables IA and B show that CD44v6 is
commonly present and is the most frequently expressed
domain in both normal basal crypt epithelium and in
colorectal tumours. To evaluate the relationship between
expression of CD44v6 as well as the other variant exons and
tumour progression, the tissue specimens were subdivided
into their Dukes' stage, indicative of the progression from
benign adenomatous polyp to colonic adenocarcinoma to
metastasis and the results are summarised in Tables I and II.
As shown in Table IB, the results show that the proportion
of specimens positive for CD44v6 is similar for benign
adenomatous polyps (85%), for advanced colon cancers
(Dukes' C, 83%) and for colorectal metastases in the liver
(Dukes' D, (80%). Similar proportions of CD44v6 positive
specimens are also found in normal mucosal specimens when
graded according to the Dukes' stage of the associated
tumour (Table IA). These data do not demonstrate a
relationship between CD44v6 expression and colonic tumour
progression.
While CD44v6 was detected as commonly in normal
mucosa as in colonic tumours, epitopes encoded by CD44v8/
9, CD44v4/5 and CD44v3 were more frequently detected in
colonic tumours compared with normal mucosa (chi-square
test: v8/9, 6.64, P=0.01; v6, 0.063, P=0.43; v4/5, 6.7,
P=0.001; v3, 4.7, P=0.03). However, like CD44v6,
CD44v4/5 and CD44v3 expression patterns were not
demonstrated to correlate with colonic tumour progression
according to Dukes' stage. Comparison of the frequency of
expression of each of the CD44 variants relative to the
Dukes' histological stage of the tumour shows that expression
of none of these epitopes is correlated with tumour
progression.
To evaluate whether the degree of CD44 variant
expression in individual tumours, that is, the proportion of
tumour cells positive for variant expression and level of
expression as judged by the intensity of staining, was related
to tumour progression, a semi-quantitative analysis was
undertaken which is summarised in Table IIA and B. These
results show that the proportion ofCD44v6-positive cells and
the intensity of CD44v6 staining remain constant throughout
each of the Dukes' stages indicating that CD44v6 was not
correlated with tumour progression by these criteria. Like-
wise, neither the proportion of colonic tumour cells positive
for the other CD44 variants nor the intensity of staining of
each of these variants was correlated with the Dukes'
histological stage of the tumour. In fact, the intensity of
staining of tumour specimens was remarkably constant for
each epitope throughout all of the Dukes' stages.
Discussion
Several studies have suggested an important biological role
for CD44 in tumour progression and metastasis, and the
potential for the use of CD44 variant expression as a
clinicopathological marker of disease progression in color-
ectal (Wielenga et al., 1993), breast (Dall et al., 1995),
pancreatic (Takada et al., 1994) and gastric cancers (Heider
et al., 1993). The finding of a relationship between CD44
variant expression and colorectal cancer progression has not
been uniform however (see Finke et al., 1995), and the results
of the present study show that CD44 variant epitopes that
have been associated with malignant transformation and
metastasis are also commonly expressed by normal colonic
epithelia. Although the variant CD44 epitopes, CD44v3,
CD44v4/5 and CD44v6, were more broadly expressed after
transformation, their expression could not be directly linked
to a more advanced or aggressive malignant phenotype,
suggesting a more complex biological role for CD44 variants
in malignancy than has been previously proposed.
The finding of a quantitative up-regulation of CD44v8-10
containing mRNA transcripts by Northern blot analysis in
tumours is consistent with previous reports (Stamenkovic et
al., 1991; Brown et al., 1991). The failure to detect other,.Mld& CD44 variants and colorectal cancer progression
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CD44 variant domains by Nothern blot is likely to be owing
to the insensitivity of this technique, as these variants and, in
particular, CD44v6 are strongly expressed at the protein
level. The three mRNA transcripts detected almost wholly
represent CD44-E, since CD44v8-10 exons are usually co-
expressed (Terpe et al., 1994). The predicted abundant
expression of the CD44v8/9 domain was not confirmed,
however, at the protein level. Although it is possible that the
mRNA transcript containing the CD44v8-10 exons is not
always translated, it appears more likely that the 1E8 MAb
has a low affinity for the CD44v8/9 epitope in situ, possibly
as a consequence of steric hindrance owing to glycosylation.
A much broader pattern of expression of the CD44v8/9
domain has been demonstrated in other laboratories using
different MAbs directed against epitopes encoded by
CD44v8- 10 (Terpe et al., 1994; Wielenga et al., 1993), and
probably reflects different antibody-binding affinities.
The wide variety of CD44 variant mRNA transcripts
detected by RT-PCR in colorectal tumours in this study is
striking. Since no pattern of exon usage particularly
distinguished tumours by Dukes' stage, a histopathological
indicator of colonic tumour progression, the proposal that
tumour metastasis can be predicted by RT-PCR of CD44
variants is not tenable. Indeed, some metastatic tumours
exhibited no CD44v6 or v7 expression, while some polyps
(non-malignant by definition) showed a diverse array of
CD44 variant mRNA transcripts containing these exons.
RT-PCR analyses demonstrate the presence of a
heterogeneous group of transcripts containing different
combinations of exons in the same tumours. These results
indicate that a complex array of CD44 variant molecules may
exist on the cell surface of many colonic tumours, and this
apparent complexity is not readily demonstrable by
immunohistochemistry alone. The data shows a tendency
for larger transcripts containing additional exons in the more
advanced tumours, but these large transcripts may also be
found in early cancers and even in some normal colonic
mucosal cells. At least eight different transcripts in colorectal
tumours were defined by RT-PCR, and there are likely to be
additional transcripts not detected by this study. Two
transcripts were identified containing the v2 exon which has
not yet been previously reported in solid tumours.
Immunohistochemical analyses of colorectal tissue speci-
mens demonstrates that CD44 variant domains encoded by
CD44v3, v4/5 and v6 are strongly expressed by at least some
tumours from each stage of tumour progression. Moreover,
the distribution of CD44 variant positive cells within tumours
is heterogeneous, with extent varying from 10 to >90% of
malignant cells carrying these epitopes. These results are at
odds with a recent report (Mulder et al., 1995) in which a
relationship was found between CD44v6 expression and
colorectal tumour progression. While the proportion of
tumours positive for CD44v6 among high-grade cancers
(Dukes' C and D) is similar in both the present study and
that of Mulder et al. (1995) (81% vs 82%), a lower rate of
colonic tumour positivity for CD44v6 among low-grade
tumours (Dukes' A and B) was found in the latter study
(Mulder et al., 1995) (92% vs 67%). The reason for this
difference is unclear, although the detection of CD44v6-
containing mRNA transcripts by RT-PCR in 85% of low-
grade colorectal tumours in the present study supports the
higher positivity rate for this epitope.
The broad extent of CD44 variant expression found in
normal colonic mucosa described in this study has not been
previously recognised. While CD44v5, v6 and v9 containing
transcripts have been detected previously in normal colonic
mucosa by RT-PCR (Wielenga et al., 1993), the respective
protein domains have not been demonstrated previously by
immunohistochemistry. In the present study, the CD44v6
epitope was detected in as many samples of normal crypt
base epithelia as in tumour specimens. CD44 epitopes v3 and
v4/5, although more restricted, were expressed in normal
colonic mucosa. Since these epitopes were largely confined to
the crypt base which is the zone of most rapid cell
proliferation, they may play a role in colonic cell
proliferation and/or differentiation. Generally, the pattern
of CD44 variant exon usage detected by exon-specific RT-
PCR in colonic tumours was similar to that seen in the
corresponding normal colonic mucosa. This is compatible
with the notion that colonic tumour cells may maintain a
similar CD44 alternative splicing pattern to the normal
mucosa from which they arose, but simply express these
epitopes in an overabundance. However, there appear to be
exceptions to this rule. In some cases, an entirely different
CD44 variant expression pattern or additional exons were
detected in the colonic tumour cells compared with the
corresponding normal mucosa. In some specimens derived
from multiple tumours from the same patients, in which
histological differentiation was an obvious variable, different
patterns of CD44 variant expression could be detected. This
situation is further complicated by the finding that in some
specimens CD44 variant expression may be observed on
normal colonocytes which are adjacent to the growing
tumour margin where, in some cases, the same CD44
variants are not detected in the tumour itself. This curious
phenomenon is not explained by current theories of induction
of CD44 variant expression in tumours (Hoffman et al., 1993;
Jamal et al., 1994), and implies the involvement of as yet
unknown trans-acting mechanisms.
This study has not provided evidence for a simple cause-
and-effect role for CD44 variant expression and tumour
progression. Conversely, the results suggest a complex role
for CD44 in colorectal malignancy. The two consistent
phenomena demonstrated are a complex array of CD44
splice variants in normal as well as malignant colonic
mucosal epithelium, and expression of variable alternatively
spliced variant CD44 transcripts in tumours, although
particular CD44 variants differ from individual to indivi-
dual. These findings do not appear to provide support for
CD44 variants as a consistent prognostic indicator for
colonic tumour progression. There is a need to determine
whether CD44 variant expression has a biological role in
human epithelial cancers or is simply an epiphenomenon.
Studies of the effects of CD44 variant expression on tumour
cell invasion and metastasis in model systems will be
important for a better understanding of the role of CD44
in tumour progression.
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